CRL
Charles River LaboratoriesNYSE
Healthcare • Diagnostics & Research
Factor tilt: Large-Cap Blend
$337.52+7.83%
Close Nov 6, 2026
- Market cap
- $16.26B
- 1 month
- +13.3%
- 3 months
- +21.8%
- 1 year
- +101.3%
- 52-week range
- $149.93$376.10
- Dividend
- No dividends on record
- Short interest
- 6.0% of float2.8M shares · settled Oct 15, 2026 · -1.5% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Sep 30, 2026
- Revenue
- $3.98B
- Net income
- $40.19M
- Free cash flow
- $399.63M
- Book value
- $3.23B
- Total debt
- $2.85B
- P/E
- 404.5×
- Price / sales
- 4.1×
- Price / book
- 5×
- FCF yield
- +2.5%
- Net margin
- +1.0%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.
Read more
This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
- Website
- criver.com
- Headquarters
- Wilmington, MA, United States
- Employees
- 18,300
- Listed
- Jun 23, 2000
- Fiscal year ends
- December
Company profile from EODHD, stored Nov 7, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Sep 2026filed Nov 4, 2026 | $982.7M | -2.2% | 36.4% | $202.6M | $333.1M |
| Jun 2026filed Aug 5, 2026 | $1.0B | -2.7% | 36.2% | $119.9M | -$1.5M |
| Mar 2026filed May 7, 2026 | $995.8M | +1.2% | 28.0% | $119.9M | -$14.8M |
| Dec 2025filed Feb 18, 2026 | $994.2M | -0.8% | 31.0% | $120.2M | -$276.6M |
| Sep 2025filed Nov 5, 2025 | $1.0B | -0.5% | 33.7% | $133.8M | $54.4M |
| Jun 2025filed Aug 6, 2025 | $1.0B | +0.6% | 34.6% | $100.1M | $52.3M |
| Mar 2025filed May 7, 2025 | $984.2M | -2.7% | 32.3% | $74.7M | $25.5M |
| Dec 2024filed Feb 19, 2025 | $1.0B | -1.1% | 28.4% | -$167.7M | -$215.7M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 18, 2026 | $4.0B | -0.9% | 30.5% | $507.8M | -$144.3M |
| Dec 2024filed Feb 19, 2025 | $4.0B | -1.9% | 32.9% | $227.3M | $10.3M |
| Dec 2023filed Feb 14, 2024 | $4.1B | +3.9% | 36.4% | $617.3M | $474.6M |
| Dec 2022filed Feb 22, 2023 | $4.0B | +12.3% | 36.8% | $651.0M | $486.2M |
| Dec 2021filed Feb 16, 2022 | $3.5B | +21.1% | 37.7% | $589.9M | $391.0M |
| Dec 2020filed Feb 17, 2021 | $2.9B | +11.5% | 36.7% | $432.7M | $364.3M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched CRL. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
2,834,023 shares short
-44,514 shares (-1.5%) vs Sep 30, 2026
6% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
2,878,537 shares short
+648,020 shares (+29.1%) vs Sep 15, 2026
6.1% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
2,230,517 shares short
-304,536 shares (-12%) vs Aug 31, 2026
Share of float unavailable. Published Sep 24, 2026.
Settlement Aug 31, 2026
2,535,053 shares short
+174,308 shares (+7.4%) vs Aug 14, 2026
5.3% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
2,360,745 shares short
-1,059,229 shares (-31%) vs Jul 31, 2026
5% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
3,419,974 shares short
+76,448 shares (+2.3%) vs Jul 15, 2026
7.2% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind CRL’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if CRL is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
60 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Oct 29, 2026
Smart-money 13F trend: distributing (heavy)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 12 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
572 filers reported a long position in CRL for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
45%
of the 56.8M shares 13-F filers reported
Moves vs Q1 2026
4 added6 trimmed
Net shares held
+5%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | FMR LLC | $961.5M · 4.2M shares | 4.2M | +22.7% |
| 2 | BlackRock, Inc. | $861.5M · 3.8M shares | 3.8M | -1.6% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | $714.2M · 3.1M shares | 3.1M | -1.7% |
| 4 | Invesco Ltd. | $676.9M · 3M shares | 3M | +24.5% |
| 5 | HARRIS ASSOCIATES L P | $508.3M · 2.2M shares | 2.2M | +4.1% |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | $501.4M · 2.2M shares | 2.2M | -3.6% |
| 7 | Allspring Global Investments Holdings, LLC | $436.5M · 1.9M shares | 1.9M | -4.4% |
| 8 | STATE STREET CORP | $422.8M · 1.9M shares | 1.9M | -0.5% |
| 9 | DIMENSIONAL FUND ADVISORS LP | $373.8M · 1.6M shares | 1.6M | -0.2% |
| 10 | ARIEL INVESTMENTS, LLC | $341.6M · 1.5M shares | 1.5M | +4.3% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of CRL file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Nov 5, 2026 | FMR LLC13G · passive · amended | 12.4% |
| Aug 13, 2026 | Invesco Ltd.13G · passive | 6.2% |
| Apr 29, 2026 | VANGUARD CAPITAL MANAGEMENT LLC13G · passive | 7.38% |
| Mar 26, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Get the Full Analysis for CRL
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.